Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of biopharmaceutical company Orexigen Therapeutics (Nasdaq: OREX) fell 10% today after a Food and Drug Administration announcement.

So what: The FDA said weight-loss pill Contrave indeed helped patients lose weight but didn't meet all the requirements. The pill may cause heart health risks, and the FDA will have a panel vote on the drug Tuesday.

Now what: Two other weight-loss drugs have been rejected by the FDA, and Contrave is now coming into question. Investors may want to wait until after Tuesday's decision to reassess this stock. We could be in for another pummeling if the panel doesn't vote favorably.

Interested in more info on Orexigen Therapeutics? Add it to your watchlist.

Fool contributor Travis Hoium does not have a position in any company mentioned. You can follow Travis on Twitter at @FlushDrawFool, check out his personal stock holdings or follow his CAPS picks at TMFFlushDraw.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.